BioVaria 2025

BioVaria 2025

ABOUT BIOVARIA

BioVaria targets technology scouts, business developers and investors highlighting commercially attractive licensing opportunities and promising startups from across Europe.

This unique event brings together Europe‘s leading tech transfer professionals, innovators from academia and start-ups with investors and representatives of the global biotech and pharma industry.

//

  • Scientists, technology transfer professionals, investors and industry scouts
  • European technology transfer organizations presenting commercially attractive licensable technologies and partnership opportunities
  • Startup Pitch & Partner featuring some of Europe’s most promising startups
  • Face-to-face discussions with investors and inventors

STARTUP PITCH & PARTNER

The interactive BioVaria Startup Pitch & Partner Programme offers start-ups from all life-science areas (pharma, diagnostics, medtech and digital health)

  • the possibility to present their technology and business concept
  • direct exchange with potential VCs and investors during speed dating
  • the opportunity to network with representatives of the industry and the life science scene

Applications are open to pre- and post-seed start-ups. Start-ups selected by an expert jury of investors will then compete live on the BioVaria stage for a “BioVaria Startup Award” worth up to 2,000 euros.

The application deadline for start-ups is February 14, 2025.

The application form can be found on our website: https://www.biovaria.org/startup-pitch-partner/startup-pitch-partner

register now

Our latest News

discover more
PL BioScience Raises the Bar in Cell Culture Technology with First Artificial Human Platelet Lysate Worldwide

PL BioScience Raises the Bar in Cell Culture Technology with First Artificial Human Platelet Lysate Worldwide

World Novelty: Artificial HPL Solution First Artificial Human Platelet Lysate BioScience Raises the Bar in Cell Culture Technology with artificial HPL PL BioScience develops worldwide first artificial Human Platelet Lysate (HPL) solution, and thus a key ingredient for the research & production of cell-based pharmaceuticals. In partnership with the Korean biotech DewCell Biotherapeutics, PL BioScience […]

EditCo Bio and Promega partner to usher in a new era of biologically relevant cell-based research

EditCo Bio and Promega partner to usher in a new era of biologically relevant cell-based research

More Information in German below. EditCo Bio und Promega schließen Partnerschaft, um eine neue Ära biologisch relevanter zellbasierter Forschung einzuläuten Redwood City, CA, USA. (12. Mai 2025) EditCo Bio, Inc. hat eine strategische Lizenzvereinbarung mit der Promega Corporation bekannt gegeben, die EditCo den Zugang zu den Technologien HiBiT, HaloTag® und NanoLuc® von Promega ermöglicht. Diese fortschrittlichen […]

Affimed Announces Filing for the Opening of Insolvency Proceedings

Affimed Announces Filing for the Opening of Insolvency Proceedings

MANNHEIM, Germany, May 13, 2025 (GLOBE NEWSWIRE) — Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced its decision to file an application for opening of insolvency proceedings with the local court of Mannheim in Germany. As previously reported, Affimed N.V. (the “Company”) […]

GET IN TOUCH

Stay Updated with bioRN’s Newsletter

Sign up for our newsletter to discover more!
* required

BioRN (BioRN Network e.V. and BioRN Cluster Management GmbH) will use the information you provide on this form to be in touch with you and to provide updates and marketing. Please let us know all the ways you would like to hear from us:

You can update your subscription preferences or unsubscribe at any time. Just follow the unsubscribe or update link in the footer of automated emails you receive from us, or by contacting us at info@biorn.org. We will treat your information with respect. For more information about our privacy practices please visit our website: www.biorn.org. By clicking below, you agree that we may process your information in accordance with these terms.

We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices.

Intuit Mailchimp